Hanny Al-Samkari, MD

Hanny Al-Samkari, MD, is the Peggy S. Blitz Endowed Chair in hematology and oncology at the Massachusetts General Hospital and an associate professor of medicine at Harvard Medical School.

Articles by Hanny Al-Samkari, MD

Systemic Bevacizumab Improves Chronic Bleeding from GI Lesions, With Hanny Al-Samkari, MD

ByHanny Al-Samkari, MD

December 19th 2025

Al-Samkari discusses a potentially novel use for bevacizumab in improving outcomes for patients with lesions from non-HHT etiologies.

Patients with HHT Exhibit More Severe Complications Than Previously Believed, With Hanny Al-Samkari, MD

ByHanny Al-Samkari, MD

December 18th 2025

Al-Samkari discusses the slew of HHT-related complications, their frequency, and their severity, highlighting the need for more active intervention.

Ianalumab Improves Stable Response, Reduces Fatigue in ITP, With Hanny Al-Samkari, MD

ByHanny Al-Samkari, MD

December 9th 2025

Al-Samkari discusses the positive results from the VAYHIT2 trial, which investigated ianalumab in combination with eltrombopag in adults with ITP.

Hanny Al-Samkari, MD

Articles by Hanny Al-Samkari, MD

Systemic Bevacizumab Improves Chronic Bleeding from GI Lesions, With Hanny Al-Samkari, MD

Patients with HHT Exhibit More Severe Complications Than Previously Believed, With Hanny Al-Samkari, MD

Ianalumab Improves Stable Response, Reduces Fatigue in ITP, With Hanny Al-Samkari, MD

Latest Updated Articles

Trending on HCPLive

New Antifibrotics Are Changing the Treatment Calculus in ILD

Q&A: Intensive LDL Lowering and Cardiovascular Prevention Strategies, With Lawrence Leiter, MD

Evaluating Clinical and Real-World Evidence in Hypercortisolism

2 Out of 3 Patients with Atopic Dermatitis Are Being Misdiagnosed

Synergy Between Metreleptin and GLP-1 Receptor Agonists in Lipodystrophy Real-World Data Suggest